Role of 11β-hydroxysteroid dehydrogenase 1 in metabolic diseases: the latest progress
10.3760/cma.j.issn.0254-9026.2021.08.028
- VernacularTitle:11β-羟基类固醇脱氢酶1型在代谢性疾病中的研究进展
- Author:
Qiyu PAN
1
;
Tingting HAN
;
Guoping LI
Author Information
1. 北京医院 国家老年医学中心 国家卫生健康委北京老年医学研究所 国家卫生健康委北京老年医学重点实验室 中国医学科学院老年医学研究院，北京 100730
- Keywords:
11β-Hydroxysteroid dehydrogenase type 1;
Glucocorticoids;
Obesity, morbid;
Diabetes Mellitus Type 2;
Fatty liver
- From:
Chinese Journal of Geriatrics
2021;40(8):1069-1074
- CountryChina
- Language:Chinese
-
Abstract:
The 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1)is the only enzyme in the body, which can convert inactive cortisone(11-dehydrocorticosterone in rodents)to active cortisol(corticosterone in rodents)in vivo.And it is vital for regulating the level of active glucocorticoids in local tissues.It has been implicated that glucocorticoid dysregulations are closely related to various metabolic diseases, such as obesity and type 2 diabetes mellitus(T2DM), etc.Therefore 11β-HSD1 may be a potential target for the treatment of metabolic diseases.In this review, we summarize the biological function and tissue distribution of 11β-HSD1, discuss how 11β-HSD1 participates in physiological and pathological mechanisms of obesity, T2DM, non-alcoholic fatty liver disease, hypertension and sarcopenia, and sum up the advanced developments of 11β-HSD1 inhibitors.
